VCM
RIGL icon

Versant Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Versant Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4K Buy
266
+29
+12% +$894 ﹤0.01% 2217
2026
Q1 		$6.41K Buy
237
+13
+6% +$437 ﹤0.01% 2316
2025
Q4 		$9.59K Hold
224
– – ﹤0.01% 2016
2025
Q3 		$6.35K Sell
224
-1
-0.4% -$30 ﹤0.01% 2113
2025
Q2 		$4.21K Buy
225
+93
+70% +$1.76K ﹤0.01% 2214
2025
Q1 		$2.38K Buy
132
+9
+7% +$183 ﹤0.01% 2247
2024
Q4 		$2.07K Buy
+123
New +$2.36K ﹤0.01% 2054

Other funds holding RIGL

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Versant Capital Management's RIGL Position: Q2 2026 in Review

Versant Capital Management increased its Rigel Pharmaceuticals (RIGL) stake by 12% in Q2 2026, buying an estimated $894 and bringing the position to 266 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2217.

Versant Capital Management first reported a position in RIGL in Q4 2024 and has held it in 7 quarters since. 7 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Versant Capital Management held 266 shares of Rigel Pharmaceuticals worth $10.4K as of Q2 2026.
  • Versant Capital Management bought 29 Rigel Pharmaceuticals shares in Q2 2026, an estimated $894.
  • Rigel Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2217 holding.
  • Versant Capital Management first reported a position in Rigel Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 7 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.